By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Regeneron Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-847-7000 Fax: n/a


Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.

Visit our website –
Check out our openings –

Key Statistics

Ownership: Public

Web Site: Regeneron
Employees: 2300+
Symbol: REGN



Sanofi US 


Geisinger Health System  Collaboration with Regeneron Genetics Center LLC, wholly-owned subsidiary of Regeneron.

Avalanche Biotech 

Company News
ERS Genomics Licenses Genome-Editing Patents To Regeneron (REGN) 11/24/2015 9:51:15 AM
Regeneron (REGN) And Sanofi (SNY) Announce 18,000-Patient ODYSSEY OUTCOMES Trial Of Praluent Injection Fully Enrolled 11/24/2015 6:09:35 AM
CVS Picks Amgen (AMGN)'s Repatha Over Sanofi (SNY)-Regeneron (REGN)'s Cholesterol Drug 11/23/2015 6:58:25 AM
Booming Regeneron (REGN) to Add 300 New Jobs in New York Following $150 Million Expansion 11/13/2015 6:35:35 AM
Sanofi (SNY) And Regeneron (REGN) Announce New Praluent (alirocumab) Injection Analyses Presented At American Heart Association Scientific Sessions 2015 11/11/2015 6:57:44 AM
Regeneron (REGN) And Sanofi (SNY) Present Results From Pivotal Phase 3 Study Of Sarilumab At American College of Rheumatology Annual Meeting 11/9/2015 6:24:18 AM
Regeneron (REGN) Release: New Survey Of U.S. Adults With Diabetes Reveals Less Than Half Understand Their Risk For Vision Loss 11/5/2015 11:14:01 AM
Sanofi (SNY) And Regeneron (REGN) To Present Results From Phase 3 Praluent (alirocumab) Injection Clinical Trials At American Heart Association Scientific Sessions 2015 11/5/2015 6:17:29 AM
Regeneron (REGN) Reports Third Quarter 2015 Financial And Operating Results 11/4/2015 9:50:48 AM
Merus Announces Final Ruling In Inequitable Conduct Case Against Regeneron (REGN) 11/4/2015 7:11:20 AM